Table 2.
Examples of oncolytic vaccinia viruses (VACVs) in clinical trials.
| Virus | Transgene | Combination | Tumor Type | Phase | Status | Reference |
|---|---|---|---|---|---|---|
| Pexa-Vec | GM-CSF | REGN2810 (anti-PD-1) | Renal cell carcinoma | I | Recruiting | NCT03294083 |
| Pexa-Vec | GM-CSF | Ipilimumab | Any except liver cancer | I | Recruiting | NCT02977156 |
| Pexa-Vec | GM-CSF | Cyclophosphamide and Avelumab | Solid tumors and soft tissue sarcoma | I & II | Recruiting | NCT02630368 |
| Pexa-Vec | GM-CSF | Sorafenib | Hepatocellular carcinoma | II | Completed | NCT01171651 |
| Pexa-Vec | GM-CSF | None | Hepatocellular carcinoma | II | Completed | NCT01636284 |
| Pexa-Vec | GM-CSF | BSC | Hepatocellular carcinoma | II | Completed | NCT01387555 |
| T601 | FCU1 | 5-Fluorocytosine | Solid tumors | I & II | Recruiting | NCT04226066 |
| TBio-6517 | FLT3L, IL-12, αCTLA-4 | Pembrolizumab | Solid Tumors | I & II | Recruiting | NCT04301011 |
| GL-ONC1 | Luc-GFP, β-Galactosidase β-glucuronidase |
Bevacizumab | Ovarian cancer, peritoneal carcinomatosis and cancer of fallopian tube | I & II | Recruiting | NCT02759588 |
| GL-ONC1 | Luc-GFP, β-Galactosidase β-glucuronidase |
None | Head and neck cancer | I | Completed | NCT01584284 |
| GL-ONC1 | Luc-GFP, β-Galactosidase β-glucuronidase |
None | Solid tumors | I | Completed | NCT00794131 |
| vvDD | Cytosine deaminase and somatostatin receptor | None | Solid tumors | I | Completed | NCT00574977 |